Year 2 of the Oncology Care Model is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Year 2 of the Oncology Care Model (OCM) is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Transcript
In terms of next steps, what does year 2 of OCM hold for you?
Year 2 is about extending the implementation that we’ve already started. So we’ve learned a lot over that year. We learned to prioritize a little bit more in terms of the data we need and how we prioritize the data as we deliver it to our clinicians. The education process, we’ve learned a little bit more about how we should structure the education process for our clinicians. So we’ve worked a lot on that. We’re looking at the workflow and how we can handle the workflow a little bit differently. We get the feedback now, the feedback loop is taking place. We’re learning what we didn’t do so well, we are learning what worked.
And our clinicians, I think, are a big change, our clinicians are engaging now in a way that they didn’t engage at the start. While they were intellectually engaged, they weren’t emotionally engaged. Now we are seeing emotional engagement. It’s that refining process that is starting to take place.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More